Use of ctDNA in early breast cancer: analytical validity and clinical potential

npj Breast Cancer, Journal Year: 2024, Volume and Issue: 10(1)

Published: June 19, 2024

Abstract Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly metastatic breast cancer, as it provides non-invasive, real-time information to complement tissue biopsies, allowing for tailored treatment strategies and improved patient selection clinical trials. Its use early cancer has been limited so far, due the relatively low sensitivity of available techniques a setting characterized by lower levels ctDNA shedding. However, advances sequencing bioinformatics, well methylome profiles, have led an increasing interest application from screening curative evaluation minimal residual disease (MRD) detection. With multiple prospective trials this setting, may become useful practice. This article reviews data regarding analytical validity currently tests detection potential cancer.

Language: Английский

---

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(5), P. 495 - 511

Published: March 29, 2024

Circulating tumor DNA (ctDNA) is the fraction of cell-free in patient blood that originates from a tumor. Advances sequencing technologies and our understanding molecular biology tumors have increased interest exploiting ctDNA to facilitate detection residual disease (MRD). Analysis as promising MRD biomarker solid malignancies has central role precision medicine initiatives exemplified by CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, underscores prognostic significance status at 4 weeks post-surgery its correlation adjuvant therapy efficacy interim analysis. This substantiates hypothesis critical indicator relapse Despite remarkable advancements, challenges endure, primarily attributable exceedingly low concentration peripheral blood, particularly scenarios shedding intrinsic error rates current technologies. These complications necessitate more sensitive sophisticated assays verify clinical utility across all tumors. Whole genome (WGS)-based tumor-informed recently demonstrated ability detect parts-per-million range. review delineates landscape assays, highlighting WGS-based approaches forefront technique Additionally, it introduces upcoming endeavor, pan-cancer via ctDNA, forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.

Language: Английский

---

Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment

Genes, Journal Year: 2025, Volume and Issue: 16(1), P. 71 - 71

Published: Jan. 9, 2025

This review provides a comprehensive overview of the evolving role minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, standard care non-metastatic CC is adjuvant chemotherapy (ACT) all stage III and high-risk II following surgical intervention. Despite 5-20% improvement in long-term survival outcomes, this approach also results significant proportion receiving ACT without any therapeutic benefit being unnecessarily exposed to risks secondary side effects. underscores an unmet clinical need more precise stratification distinguish who necessitate from those can be treated surgery alone. By employing liquid biopsy, it possible discern MRD enabling categorization as MRD-positive or MRD-negative, potentially revolutionizing management ACT. aimed examine heterogeneity methodologies currently available detection, encompassing state-of-the-art technologies, their respective advantages, limitations, technological challenges multi-omic approaches that utilized enhance assay performance. Furthermore, discussion was held regarding trials employ focusing on assays used. These differences methodology, target selection, performance risk producing inconsistent may not solely reflect biological/clinical but consequence preferential use particular products studies conducted different countries. Standardization harmonization will crucial ensure revolution delivers reliable clinically actionable outcomes patients.

Language: Английский

---

The Potential Role of Circulating Tumor DNA as a Tool in the Management of Gastrointestinal Malignancies

Advances in Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

BMC Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Aug. 15, 2023

Abstract Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a ctDNA analysis MONALEESASIA, phase Ib trial evaluating efficacy and safety ribociclib plus endocrine therapy (ET) Asian patients with hormone receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer. Methods MONALEESASIA enrolled premenopausal postmenopausal Japanese non-Japanese patients. All received ET (letrozole, fulvestrant, or tamoxifen goserelin). was analyzed using targeted next-generation sequencing panel 572 cancer-related genes correlated by best overall response (BOR). Results Five hundred seventy-four cell-free samples from 87 were tested. The most frequently altered at baseline included PIK3CA (29%) TP53 (22%). Treatment decreased first on-treatment time point, regardless dose partner. Patients partial stable disease had lower that remained low until cutoff if no progressive occurred. Most as higher high end treatment. For subsequent progression, increased towards treatment patients, median lead 83 days (14–309 days). In some BOR who experienced progression later, specific gene alterations total fraction increased; this sometimes observed concurrently development new lesions without change target lesion size. shorter progression-free survival compared wild-type , 12.7 7.3 months vs 19.2 19.4 months, respectively ( P = .016 .0001, respectively). Conclusions Higher levels detected associated inferior outcomes. On-treatment different patterns based BOR. Longitudinal tracking may be useful for monitoring status detection implications. Trial registration ClinicalTrials.gov NCT02333370 . Registered January 7, 2015.

Language: Английский

---

Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer

Current Oncology Reports, Journal Year: 2024, Volume and Issue: unknown

Published: June 6, 2024

Language: Английский

---

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy

Annals of Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---

Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?

The Journal of Liquid Biopsy, Journal Year: 2023, Volume and Issue: 3, P. 100132 - 100132

Published: Dec. 12, 2023

Despite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due occult micrometastasis. The minimal residual disease (minimal RD) EBC patients after the with curative intent cannot be easily detected by clinical examination and radiological imaging, as they are both burdened limited sensitivity. A new frontier promising approach address this unmet need is study liquid biopsy (LB). most studied tumor-derived analytes peripheral blood RD monitoring currently: i) circulating tumor DNA (ctDNA), detection somatic alterations, so referred molecular (MRD); ii) cells (CTCs), cellular (CRD). MRD detection, while reaching high specificity, still presenting number limitations. On other hand, CRD allows real-time monitoring, detecting live cells, possess potential provide an enormous amount biological information. Indeed, CTCs can multi-level portrait (i.e., DNA, RNA proteins) tumor, longitudinally depicting its evolving landscape, used functional (in vitro/in vivo) characterization. Moreover, goes beyond association risk recurrence: predictive biomarkers response also evaluated. Nevertheless, less context, because their immediately processed small fraction post-surgery setting. These limitations could however overcome use newly developed technologies that enable increased CTC rate retrospective studies. Here, we review strengths using focusing on methodologies available LB analysis setting, main studies investigating EBC. Considering limits advantages CRD, propose integration ctDNA complementary tools assessment achieve synergistic novel analysis.

Language: Английский

---

Glycoproteomics-based liquid biopsy: translational outlook for colorectal cancer clinical management in Southeast Asia

Future Oncology, Journal Year: 2023, Volume and Issue: 19(34), P. 2313 - 2332

Published: Nov. 1, 2023

Colorectal cancer (CRC) signifies a significant healthcare challenge in Southeast Asia. Despite advancements screening approaches and treatment modalities, medical gaps remain, ranging from prevention early diagnosis to determining targeted therapy establishing personalized managing CRC. There is need expand more validated biomarkers clinical practice. An advanced technique incorporating high-throughput mass spectrometry as liquid biopsy unravel repertoire of glycoproteins glycans would potentially drive the development tools for CRC screening, monitoring, it can be further adapted existing standard-of-care procedure. Therefore this review offers perspective on glycoproteomics-driven its potential integration into care southeast Asia region.

Language: Английский

---

Understanding the Landscape of Clinically Available Molecular Testing

Surgical Oncology Clinics of North America, Journal Year: 2024, Volume and Issue: 33(2), P. 217 - 230

Published: Jan. 29, 2024

Language: Английский

---